<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34448999</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1590-3478</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title>
          <ISOAbbreviation>Neurol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Zonisamide in Parkinson's disease: a current update.</ArticleTitle>
        <Pagination>
          <StartPage>4123</StartPage>
          <EndPage>4129</EndPage>
          <MedlinePgn>4123-4129</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-021-05550-2</ELocationID>
        <Abstract>
          <AbstractText>Parkinson's disease (PD) is a progressive neurodegenerative disease due to the depletion of the neurotransmitter dopamine in basal ganglia. There is a scarcity of available therapies for motor and non-motor symptoms of PD. Zonisamide (ZNS) may be one such potential candidate to alleviate PD symptoms. It was serendipitously found to be useful for PD in a patient with both epilepsy and PD. Since then, there have been many clinical trials, case series, observational studies, and case reports published supporting the efficacy of ZNS in PD. This review focuses on the efficacy and usefulness of ZNS in various motor and non-motor symptoms of PD. A predefined inclusion and exclusion criteria were used for the search protocol and databases searched were PubMed, Cochrane Library, Ovid, and clinicaltrials.gov. Most of the randomized clinical trials used UPDRS III as the primary efficacy point and showed positive results favouring ZNS. This review shows that there is evidence of the efficacy of ZNS in motor symptoms as an adjunctive therapy to levodopa, but for non-motor symptoms, the evidence is lacking and needs further investigation.</AbstractText>
          <CopyrightInformation>© 2021. Fondazione Società Italiana di Neurologia.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Goel</LastName>
            <ForeName>Atul</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugumaran</LastName>
            <ForeName>Ramkumar</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-4007-4640</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Dhanvantri Nagar, Puducherry, 605006, India. ramkumar.sugumaran@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Narayan</LastName>
            <ForeName>Sunil K</ForeName>
            <Initials>SK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Jawaharlal Institute of Postgraduate Medical Education and Research, Gorimedu, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Italy</Country>
        <MedlineTA>Neurol Sci</MedlineTA>
        <NlmUniqueID>100959175</NlmUniqueID>
        <ISSNLinking>1590-1874</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>46627O600J</RegistryNumber>
          <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>VTD58H1Z2X</RegistryNumber>
          <NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Movement disorders</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
        <Keyword MajorTopicYN="N">Tremors</Keyword>
        <Keyword MajorTopicYN="N">UPDRS</Keyword>
        <Keyword MajorTopicYN="N">Zonisamide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>27</Day>
          <Hour>12</Hour>
          <Minute>32</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34448999</ArticleId>
        <ArticleId IdType="doi">10.1007/s10072-021-05550-2</ArticleId>
        <ArticleId IdType="pii">10.1007/s10072-021-05550-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Reimers A, Ljung H (2019) An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. Expert OpinPharmacother 20(8):909–915</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2019.1595584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilfong AA, Willmore LJ (2006) Zonisamide – a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2(3):269–280</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/nedt.2006.2.3.269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bermejo PE, Dorado R (2009) Zonisamide for migraine prophylaxis in patients refractory to topiramate. Clin Neuropharmacol 32(2):103–106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNF.0b013e318170577f</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moore RA, Wiffen PJ, Derry S, Lunn MP. Zonisamide for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;1(1):CD011241.</Citation>
        </Reference>
        <Reference>
          <Citation>Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N (2011) Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol Bull 44(1):5–17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22506436</ArticleId>
            <ArticleId IdType="pmc">5044556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D’Alessio DA, Keck PE, Hudson JI (2006) Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 67(12):1897–1906</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/JCP.v67n1209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapoport AM, Bigal ME (2004) Preventive migraine therapy: what is new. Neurol Sci 25:s177–s185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-004-0281-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harbor Perspect Biol 10(4):a033118</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a033118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuda Y, Ishizaki M, Shimizu M (1998) Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev 4(4):341–360</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1527-3458.1998.tb00075.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oki M, Kaneko S, Morise S, Takenouchi N, Hashizume T, Tsuge A et al (2017) Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats. Neurosci Res 122:45–50</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neures.2017.04.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topçu Y, Bayram E, Özbal S, Yiş U, Tuğyan K, Karaoğlu P et al (2014) Zonisamide attenuates hyperoxia-induced apoptosis in the developing rat brain. Neurol Sci 35(11):1769–1775</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-014-1834-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duty S, Jenner P (2011) Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164(4):1357–1391</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1476-5381.2011.01426.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arawaka S, Fukushima S, Sato H, Sasaki A, Koga K, Koyama S et al (2014) Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson’s disease. PLOS ONE. 9(2):e89076</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0089076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gluck M, Santana L, Granson H et al (2004) Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson’s activity. J Neural Transm 111:713–724</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00702-004-0107-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Amico D (2007) Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci 28:S188–S197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-007-0775-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41(4):397–399</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0168-0102(01)00298-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanishi I, Kohmoto J, Miwa H, Kondo T (2003) No to shinkei = brain and nerve. 55(8):685–689</Citation>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I (2004) The Japan Zonisamide Study Group. Randomized, double-blind study of zonisamide with placebo in advanced Parkinson’s disease. Mov Disord 19:P555. MovDisord 200419P555.</Citation>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group (2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68(1):45–50.</Citation>
        </Reference>
        <Reference>
          <Citation>Kajimoto Y, Nakanishi I, Kondo Wakayama T (2008) I. One year follow-up study of the zonisamide (ZNS) efficacy on parkinsonism. MovDisord 23Suppl 1 214 Abstr</Citation>
        </Reference>
        <Reference>
          <Citation>Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R et al (2015) Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. MovDisord Off J MovDisord Soc 30(10):1343–1350</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.26286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M et al (2018) Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology 90(8):e664–e672</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000005010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cha P-C, Satake W, Ando-Kanagawa Y, Yamamoto K, Murata M, Toda T (2020) Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients. J Hum Genet 65(8):693–704</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s10038-020-0760-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bruno E, Nicoletti A, Filippini G, Quattrocchi G, Colosimo C, Zappia M (2017) Zonisamide for essential tremor. Cochrane database System Rev 8(8):CD009684</Citation>
        </Reference>
        <Reference>
          <Citation>Song IU, Kim JS, Lee SB, Ryu SY, An JY, Kim HT, Kim YI, Lee KS (2008) Effects of zonisamide on isolated head tremor. Eur J Neurol 15(11):1212–1215</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1468-1331.2008.02296.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekimoto S, Oyama G, Izawa N, Ueno S, Jo T, Shimo Y, Nakajima A, Nakajima M, Umemura A, Arai H, Hattori N (2016) Effect of zonisamide on post-traumatic Holmes’ tremor. Neurol Clin Neurosci 4:184–185</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ncn3.12063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol 257(10):1682–1685</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-010-5603-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C (2009) Zonisamide combined with cognitive behavioral therapy in binge eating disorder. Psychiatry Edgmont 6(11):23–28</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20049147</ArticleId>
            <ArticleId IdType="pmc">2801482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinrys G, Vasconcelos e Sa D, Nery F (2007) Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61(6):1050–3</Citation>
        </Reference>
        <Reference>
          <Citation>White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK (2010) Zonisamide discontinuation due to psychiatric and cognitive adverse events. Neurology 75(6):513</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181eccfb5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. MovDisord 26(S3):S2-41</Citation>
        </Reference>
        <Reference>
          <Citation>Fox SH, Katzenschlager R, Lim S-Y, Barton B, de Bie RMA, Seppi K et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease: treatment of motor symptoms in PD. MovDisord 33(8):1248–1266</Citation>
        </Reference>
        <Reference>
          <Citation>Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al (2016) Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Sibley DR, editor. Pharmacol Rev 68(3):563</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
